

APTORUM

OUR MISSION IS TO FACILITATE LIFE SCIENCE INNOVATIONS TO SERVE UNMET MEDICAL NEEDS

Corporate Presentation

NASDAQ GLOBAL MARKET IPO – Anticipated Q4 2018

Underwritten By:

Boustead Securities

China Renaissance

尚乘老虎 AMTD TIGER

FWP Issuer Free Writing Prospectus

Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended

Registration Statement No. 333-227198

The issuer has filed a registration statement (including a preliminary prospectus) with the SEC for the offering to which this communication relates (file no. 333-227198). Before you invest, you should read the preliminary prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting SEC EDGAR web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus if you request it by calling +1(949)502-4409.

To review a filed copy of our current registration statement, click on the following link:

https://www.sec.gov/Archives/edgar/data/1734005/000121390018013586/ff12018a1_aptorumgroup.htm

APTORUM

DISCLAIMER

Aptorum Group Limited has filed a registration statement (including a preliminary prospectus) with the SEC for the offering to which this communication relates (file no. 333-227198). Before you invest, you should read the preliminary prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting SEC EDGAR web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus if you request it by calling +1(949)502-4409.

All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements. The words "believe," "estimate," "anticipate," "expect," "plans," "intend," "may," "could," "might," "will," "should," "approximately," "potential," and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may effect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the "Risk Factors" section of the preliminary prospectus. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this preliminary prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

All references to dollar amounts in the offering summary or to use of proceeds are subject to change pending a final prospectus.

OFFERING SUMMARY

ISSUER	Aptorum Group Limited
SECURITY	Class A Ordinary Shares
TICKER / EXCHANGE	APM on Nasdaq Global Market (Expected)
SHARES OUTSTANDING PRIOR TO COMPLETION OF OFFERING	5,426,381 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares
SHARES OFFERED	645,161 to 1,935,484 based on minimum and maximum offering size, calculated at US$15.50 per share, mid-point of the price range
PRICE RANGE	US$14.50 - US$16.50
OFFERING SIZE	US$10,000,000 to US$30,000,000
LOCK-UP AGREEMENT	Lock-up period of six months for the series A note investors and 90 calendar days for the bond holder. Six-month lock-up period for all directors, officers and certain shareholders
USE OF PROCEEDS	• To fund the preclinical and clinical development of lead projects (ALS-1, ALS-4 and NLS-1) through Phase 1 • To fund the development of non-therapeutic projects • To fund the set up of Aptorum's self-owned laboratory in Fo Tan, Hong Kong • To fund other non-lead projects under development (other than non-therapeutic projects), general research and development activities, working capital, and other general corporate activities
UNDERWRITERS	Boustead Securities, LLC, China Renaissance Securities (HK) Limited and AMTD Global Markets Limited
EXPECTED PRICING DATE	October 2018

See the offering documents for full risks and disclosures.

APTORUM

INVESTMENT HIGHLIGHTS



- Portfolio of molecules intended to diagnose or treat MRSA, Influenza, Endometriosis, etc.
- Management team coupled with medical talents and prominent scientific advisory board
- Board of directors with diverse background and accomplishments in finance and in healthcare industry
- Located in Hong Kong with proximity and access to the first 3 CFDA-accredited facilities outside China to carry out clinical trials, including The University of Hong Kong, The Chinese University of Hong Kong, and Hong Kong Eye Hospital
- Pre-IPO investor base including Adamas Ping An Opportunities Fund[1] and medical professionals

[1] Adamas Ping An Opportunities Fund L.P. is the third fund from Adamas Asset Management (HK) Limited ("Adamas") and the first fund from the joint venture between Adamas and Yun Sheng Capital Company Limited, a subsidiary of Ping An Insurance (Group) Company of China Limited and is advised by Ping An Capital Company Limited.

BUSINESS MODEL



* Decisions on whether to continue development and commercialization of our early-stage projects would heavily depend on the relevant preclinical and clinical data and trial results. The Company expects to follow the business model outlined above.

For illustrative purposes only. There is no guarantee of any outcome from any clinical trial.

APTORUM

LEADERSHIP

MR. IAN HUEN

Founder, Chief Executive Officer and Executive Director

- Over 15 years in global asset management
- US healthcare equity research analyst at Janus Henderson Group
- Trustee board member of Dr. Stanley Ho Medical Development Foundation
- CFA, Princeton University (Econ)

MR. DARREN LUI

President, Chief Business Officer and Executive Director

- Over 13 years in global capital market
- Extensive exposure in UK, Singapore, US, etc.
- ICAS, CFA & Associate of Chartered Institute of Securities & Investments (UK)
- First-Class Honors from Imperial College (Biochemistry)

DR. CLARK CHENG

Chief Medical Officer and Executive Director

- Almost 10 years working in Raffles Medical Group as Operations Director and Deputy General Manager
- Received medical training at the University College London in 2005 & obtained membership of the Royal College of Surgeons of Edinburgh in 2009
- MBA, University of Iowa

DR. KEITH CHAN

Chief Scientific Officer

- Over 38 years in pharmaceutical and biotech development
- Specialize in technology transfers and licensing deals and regulatory submissions to the FDA
- Former Director of Division of Bioequivalence responsible for managing and approval of generic drugs in US

MISS SABRINA KHAN

Chief Financial Officer

- Almost 10 years serving US & Asian healthcare companies
- Extensive experience in business development, restructuring, US & Asian IPO, and M&A deals
- Solid accounting experience gained from Big 4
- Advanced China Certified Taxation Consultant
- CPA, the University of Hong Kong (BBA(Acc & Fin))

DR. THOMAS LEE WAI YIP

Chief Executive Officer & Chief Scientific Officer - Aptorum Therapeutics Limited

- Former Assistant Professor at The Chinese University of Hong Kong (CUHK) specialized in drug delivery and formulation development
- 10 years working at Novartis & Celgene
- B.Pharm.(Hons), CUHK; Ph.D. in Pharmaceutical Sciences (Drug Delivery), the University of Wisconsin-Madison

INDEPENDENT NON-EXECUTIVE DIRECTORS

PROFESSOR
DOUGLAS ARNER

Independent Non-Executive Director

Kerry Holdings Professor in Law, HKU

DR.
JUSTIN WU

Independent Non-Executive Director

Associate Dean, Faculty of Medicine, CUHK

DR.
MIRKO SCHERER

Independent Non-Executive Director

CEO of TVM Capital China

MR.
CHARLES BATHURST

Independent Non-Executive Director

Founder of Summerhill Advisors Limited

SCIENTIFIC ADVISORS

DR.
NISHANT AGRAWAL

Senior Clinical Advisor

Professor of Surgery, School of Medicine, University of Chicago

DR.
HENRY CHAN LIK YUEN

Senior Advisor

Associate Dean, Faculty of Medicine, CUHK

DR.
PHILIP W.Y. CHIU

Senior Advisor

Professor, Department of Surgery, Institute of Digestive Disease, CUHK

DR.
VINCENT MOK CHUNG TONG

Senior Advisor

Head of Division of Neurology, Dept of Medicine & Therapeutics, CUHK

DR.
KENNY YU KWOK HEI

Scientific Assessment Committee Member

NIHR Academic Clinical Lecturer, the University of Manchester

DR.
KA-WAI KWOK

Scientific Assessment Committee Member

Asst. Professor, Department of Mechanical Engineering, the University of Hong Kong

DR.
JASON Y. K. CHAN

Scientific Assessment Committee Member

Asst. Professor, Department of Otorhinolaryngology, CUHK

DR.
OWEN KO HO

Scientific Assessment Committee Member

Asst. Professor, Department of Medicine and Therapeutics, CUHK

DR.
WAI-LUNG NG

Scientific Assessment Committee Member

Research fellow, Dana-Farber Cancer Institute/ Harvard Medical School

DR.
SUNNY WONG HEI

Scientific Assessment Committee Member

Asst. Professor, Department of Medicine and Therapeutics, CUHK

DR.
WILLIAM WU KA KEI

Scientific Assessment Committee Member

Asso. Professor, Department of Anaesthesia and Intensive Care, CUHK

PROJECT PORTFOLIO

DRUG AND DEVICE CANDIDATES										
PROJECTS	CANDIDATE / MODALITY	INDICATION	DEVELOPMENT STAGE						
			Target Identification & Selection	Lead Discovery	Lead Optimization	IND-Enabling	Phase 1	Phase 2	Phase 3
VIDENS' SERIES									
VLS-1	Curcumin-MNP (Medical Imaging Agent for MRI Diagnosis)	Diagnosis of Alzheimer's Disease							
VLS-2	MITA (mTor-independent TFEB activator)	Treatment of Alzheimer's & Parkinson's Disease							
VLS-3	Non-Invasive Retina Imaging Diagnostics	Diagnosis of Alzheimer's Disease							
VLS-4	Imaging Agent for MRI Diagnosis	Diagnosis of Alzheimer's Disease							
ACTICULE'S SERIES									
ALS-1	Small Molecule	Treatment of viral infections caused by Influenza virus A							
ALS-2	Small Molecule	Treatment of bacterial infections caused by Staphylococcus aureus including MRSA							
ALS-3	Small Molecule	Reviving existing antibiotics to overcome drug resistance							
ALS-4	Small Molecule	Treatment of bacterial infections caused by Staphylococcus aureus including MRSA							

Lead Projects Other Candidates Device Candidates

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

APTORUM

PROJECT PORTFOLIO

PROJECTS	CANDIDATE / MODALITY	INDICATION	DEVELOPMENT STAGE						
			Target Identification & Selection	Lead Discovery	Lead Optimization	IND-Enabling	Phase 1	Phase 2	Phase 3
NATIVUS' SERIES									
NLS-1	Small molecule	Treatment of Endometriosis							
NLS-2	An extract from Chinese yam	Relief of Menopausal Symptoms							
NLS-3	SAC	Treatment of and protection against retinal ischemia/ reperfusion injury							
SCIPIO'S SERIES									
SPLS-1	83b-1 Novel Quinoline Derivative	Treatment of liver cancer							

PROJECTS	CANDIDATE / MODALITY	INDICATION	DEVELOPMENT STAGE					
			Lab-based Phantom Trial	Animal Trial	IDE Application Approval	Safety/Fesibility Clinical Study	Pivotal Clinical Study	Process of obtaining PMA
SIGNATE'S SERIES								
SLS-1	Robotic catheter platform for Intra-operative MRI-guided cardiac catheterization	Heart rhythm disorders by cardiac electrophysiology intervention	On-going					

Lead Projects Other Candidates Device Candidates

OTHER KEY PROJECTS			
ALS-DDC	Drug Discovery Center + Chemical Library	Drug discovery by identification and screening of drug molecules for various indications	Setting Up
AML Clinic	Clinic - Talem Medical	Medical Services	Commenced operations in June 2018

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

OVERVIEW OF OUR LEAD PROJECTS



ALS-1 INFLUENZA A	ALS-4 STAPHYLOCOCCUS INCLUDING METHICILLIN-RESISTANT S. AUREUS (MRSA)	NLS-1 ENDOMETRIOSIS
Population affected: Annual epidemics estimated to result in ~3-5 million cases of serious influenza infections, causing about 290,000-650,000 deaths each year[i], around 50-80% of influenza infections are type A[ii].	Population affected: 53 million people worldwide carry MRSA[i]. For example, in U.S., ~126,000 hospitalizations are due to MRSA yearly, where severe infections occur in ~94,000 people each year and are associated with ~19,000 deaths[ii].	Population affected: ~176 million women globally (≈1 in 10 women during their reproductive years)[i]. ~30-40% of women with endometriosis are subject to risk of infertility and may develop complications during pregnancy[ii].
Market Size: Global Market Size in 2016: US$ 0.60 billion[iii]. Expected Global Market Size by 2025: US$ 1.2billion[iii].	Market Size: Global Market Size in 2016: US$ 2.97 billion[iii]. Expected Global Market Size by 2025: US$ 3.91 billion[iii].	Market Size: Market Size in 2015: US$ 1.72 billion (across the 7 major countries)[iii]. Expected Market Size by 2025: just over US$ 2 billion (across the 7 major countries)[iii].

i. WHO: Influenza (Seasonal). http://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal)
ii. WHO Global circulation of influenza viruses. http://apps.who.int/flumart/Default?ReportNo=6
iii. Bloomberg: New Drugs Are Coming to Fight Nasty Flu Seasons (9 Feb 2018). https://www.bloomberg.com/news/articles/2018-02-08/flu-relief-is-coming-as-successors-to-aging-tamiflu-near-market

i. Roche Annual report 2017. https://www.roche.com/dam/jcr:78519d71-10af-4e02-b490-7b4648a5edb8/en/ar17e.pdf
ii. emedicinehealth: MRSA https://www.emedicinehealth.com/mrsa_infection/article_em.htm#how_common_is_mrsa
iii. Healthcare Drive: Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast Predictions. https://www.healthcaredrive.com/press-release/20180405-global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-anal/

i. Endometriosis.org: Facts about endometriosis. http://endometriosis.org/resources/articles/facts-about-endometriosis/
ii. Washington University Physicians, "Endometriosis", https://fertility.wustl.edu/getting-started-infertility/infertility-factors/endometriosis/
J. Fisher M. Kirkman, "Endometriosis and fertility: women's accounts of healthcare", Human Reproduction, Volume 31, Issue 3, March 1, 2016, Pages 554–562, January 11, 2016, https://doi.org/10.1093/humrep/dev337
iii. R&D: Endometriosis Market Expected to Surpass $2 Billion by 2025 (11 Nov 2016) – By Global Data. List of 7 major countries: the US, France, Germany, Italy, Spain, the UK and Japan. https://www.rdmag.com/news/2016/11/endometriosis-market-expected-surpass-2-billion-2025

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

APTORUM

LEAD PROJECT - ALS-1

A SMALL MOLECULE FOR THE TREATMENT OF VIRAL INFECTIONS CAUSED BY INFLUENZA VIRUS A

CHARACTERISTICS

- Small drug molecule
- ALS-1 acts on a unique therapeutic target, nucleoproteins, which distinguishes it from all other currently marketed antiviral drugs which currently experience resistance from Influenza A virus

MECHANISM OF ACTION

- We believe the therapeutic target, nucleoproteins, is essential for proliferation of viruses

ADMINISTRATION

- We intend to develop this molecule for oral administration





This figure shows the concentration dependence of ALS-1 in reducing the plaque-forming unit (pfu, a measure of number of infectious virus particulates, which represents the in vitro efficacy of the drug) of human H1N1, H3N2 and H5N1 influenza viruses. The IC_{50} (the concentration of drug at which 50% of the virus is inhibited) for these viruses is between 0.1-1μM. Oseltamivir (curve in red) is included for comparison in terms of in vitro efficacy against H1N1. The curve of ALS-1 is in the left side of the red curve, indicating ALS-1 has a lower IC_{50}.

[Adapted from Nature Biotechnology [28 (6): 600, 2010]]

This figure shows that MDCK cells were infected and ALS-1 (1 μM) was added before infection (−1 h), at the time of infection (0 h) and at 1, 2, 4, 6 and 8 hour after infection as indicated. + = a control without ALS-1. This figure indicates that ALS-1 inhibited viral growth even when added within 6 hours after inoculation of the MDCK cells with the virus, indicating that the antiviral activities of ALS-1 reside on post-entry and post-nuclear events, suggesting that multiple processes involving NP may be affected.

[Adapted from Nature Biotechnology [28 (6): 600, 2010]]

APTORUM

CURRENT TREATMENT OPTIONS

FOR VIRAL INFECTIONS CAUSED BY INFLUENZA VIRUS A

COMPANY	PRODUCT (GENERIC NAME)	PRODUCT (BRAND NAME)	FORMULATION	FDA APPROVAL (YEAR)	AVAILABILITY OF GENERIC VERSIONS
GlaxoSmithKline (GSK)	Zanamivir	Relenza	Powder	1999	N
Roche	Oseltamivir	Tamiflu	Capsule, for Suspension	1999	Y
Seqirus	Peramivir	Rapivab	Intravenous	2014	N

- ALS-1 acts on a unique therapeutic target, nucleoproteins, which distinguishes it from all other currently marketed antiviral drugs which currently experience resistance from Influenza A virus.
- Inhibition of virus replication in vitro and outperforms oseltamivir (Tamiflu®) with a lower IC_{50} (half maximal effective concentration).
- Animal studies suggest that ALS-1 has the potential to be developed into a useful anti-influenza therapeutic.

Reference:
FDA: FDA Approved Drug Products: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
MedicineNet.com: https://www.medicinenet.com

LEAD PROJECT - ALS-4

A SMALL MOLECULE FOR THE TREATMENT OF INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS INCLUDING MRSA

CHARACTERISTICS

- MRSA has developed resistance to many, if not all, of the existing drugs available for treatment
- Intended to inhibit formation of golden color pigment that enables bacteria to invade cells and also avoid attack by the immune system

MECHANISM OF ACTION

- Intended to inhibit golden color pigment formation, an important factor in promoting the bacteria to invade healthy cells, and to protect them from attack by immune system

ADMINISTRATION

- We intend to develop this molecule for oral or IV administration

LEAD PROJECT - ALS-4

A SMALL MOLECULE FOR THE TREATMENT OF INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS INCLUDING MRSA





ALS-4 has been developed to inhibit the formation of the golden pigment in vitro in a dose-dependent manner.

The IC_{50} of ALS-4 for the inhibition of the golden pigment formation is roughly 300nM.

All data represent mean values ± SD.
NP16 = ALS-4
This assay was conducted in triplicate and repeated twice for confirmation

[Adapted from mBio [8[5]: e01224, 2017]]

APTORUM

CURRENT TREATMENT OPTIONS

FOR MRSA

PRODUCT (GENERIC NAME)	
Cefazolin	Dicloxacillin
Cefuroxime	Vancomycin
Cephalexin	Clindamycin
Nafcillin	Rifampin
Oxacillin	Telavancin

- MRSA has developed resistance to many, if not all, of the existing drugs available for treatment.
- ALS-4 employs a non-antibiotic approach designed to act on a unique therapeutic target to inhibit production of staphyloxanthin, which distinguishes it from other current treatments.
- Studies have shown that staphyloxanthin is an important factor in enabling MRSA bacteria to escape from the immune system.
- ALS-4 has been developed to inhibit production of staphyloxanthin without killing the bacteria, which should enable the immune system to clear MRSA.

REFERENCE:
MedicineNet.com: Staph Infection: https://www.medicinenet.com/staph_infection/article.htm#what_is_antibiotic-resistant_s_aureus

APTORUM

LEAD PROJECT - NLS-1

PRO-EGCG, A DERIVATIVE OF EPIGALLOCATECHIN-3-GALLATE FOR THE TREATMENT OF ENDOMETRIOSIS

CHARACTERISTICS

- Drug molecule derived from a small molecule extracted from green tea
- Non-hormonal treatment

MECHANISM OF ACTION

- Act as an antiangiogenic therapy

ADMINISTRATION

- We intend to develop this molecule for oral administration

LEAD PROJECT - NLS-1

PRO-EGCG, A DERIVATIVE OF EPIGALLOCATECHIN-3-GALLATE FOR THE TREATMENT OF ENDOMETRIOSIS



Studies utilizing mouse endometriosis models demonstrated that administration of NLS-1 resulted in greater reductions in the size and weight of lesions than Vitamin E, EGCG or the control without any treatment molecule.

[Adapted from Angiogenesis (16:59, 2013)]



Studies utilizing mouse endometriosis models demonstrated that administration of NLS-1 resulted in greater reductions in angiogenesis than Vitamin D, EGCG or the control without any treatment molecule.

[Adapted from Angiogenesis (16:59, 2013)]

APTORUM

CURRENT TREATMENT OPTIONS
FOR ENDOMETRIOSIS

CURRENT HORMONAL TREATMENTS

PRODUCT (GENERIC NAME)	
GnRH agonist	Leuprorelin
	Goserelin
	Nafarelin
	Buserelin
	Triptorelin
Progestins	Dienogest
	Medroxyprogesterone acetate
	Depot medroxyprogesterone acetate
	Norethisterone
Danazol	
Aromatase Inhibitors	
Oral contraceptive pills	
Mirena coils	

- Drug molecule derived from EGCG which is extracted from green tea.
- Intended as non-hormonal treatment for endometriosis.
- Studies in animal models show reductions in development, growth and angiogenesis of endometriosis greater than EGCG.
  - Statistically significant reduction in the development, growth and angiogenesis of endometriosis.
- We believe our treatment may provide an alternative to hormonal treatments which have undesirable side effects.
  - Statistically significant reduction in the lesion size over oral EGCG and other hormone-based therapy in animal models.

REFERENCE:
Endometriosis.org: Treatments: http://endometriosis.org/treatments
Endometriosis.org: GnRH: http://endometriosis.org/treatments/gnrh/
Endometriosis.org: Progestins: http://endometriosis.org/treatments/progestins/

OTHER PROJECTS UNDER DEVELOPMENT

ALS-2

- A small molecule targeting bacterial virulence for the treatment of bacterial infections caused by Staphylococcus aureus including MRSA, by suppressing the expression of multiple virulence factors simultaneously.
- Currently at the Lead Optimization Stage to optimize its drug-like properties.

ALS-3

- A small molecule that is presently under investigation to combine with certain classes of existing antibiotics to overcome drug resistance.
- Currently at the Lead Optimization Stage to optimize its drug-like properties.

VLS-1

- An MRI contrast agent, which may enable imaging for identifying amyloid beta plaques in Alzheimer's disease.
- Currently at the Lead Discovery Stage.

VLS-3

- Consists of two components, a curcumin oral formulation and an integrated retinal imaging system for diagnosis of Alzheimer's disease.
- Currently at the Lead Discovery Stage.

VLS-4

- Developing a new class of MRI contrast agents for diagnosis of neurodegenerative diseases.
- Currently at the Lead Discovery Stage.

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

OTHER PROJECTS UNDER DEVELOPMENT

VLS-2

- We believe VLS-2 is a small drug molecule that appears to activate autophagy without inhibiting mTOR function, an endogenous cellular mechanism for clearing multiple pathological protein aggregates including tau, which are responsible for the development of neurodegenerative diseases.
- Currently at the Lead Discovery Stage.

NLS-2

- Extract isolated from Chinese Yam, Dioscorea opposita Thunb, in development for the treatment of menopausal syndrome.
- Currently at the Lead Discovery Stage.

NLS-3

- Extract from garlic S-allyl L-Cysteine (SAC) for the treatment of and protection against retinal ischemia/reperfusion injury.
- Currently at the Lead Discovery Stage.

SPLS-1

- A quinoline derivative from Ephedra pachyclada, is at present under active investigation for the treatment of liver cancer.
- Currently at the Lead Discovery Stage.

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

APTORUM

DEVICE UNDER DEVELOPMENT

PROJECTS	CANDIDATE / MODALITY	INDICATION	DEVELOPMENT STAGE					
			Lab-based Phantom Trial	Animal Trial	IDE Application Approval	Safety/Fesibility Clincial Study	Pivotal Clinical Study	Process of obtaining PMA
SIGNATE'S SERIES								
SLS-1	Robotic catheter platform for Intra-operative MRI-guided cardiac catheterization	Heart rhythm disorders by cardiac electrophysiology intervention	On-going					



- Robotic catheter platform for MRI-guided cardiovascular intervention for the treatment of arrhythmia.
- The platform consists of a magnetic resonance imaging ("MRI-guided") robotic electrophysiology ("EP") catheter system, an MR-based positional tracking unit, and a navigation interface.
- Currently in Lab-based Phantom Trial, followed by preclinical trials when all the components are ready.

OTHER NON-THERAPEUTIC PROJECTS

OTHER KEY PROJECTS			
ALS-DDC	Drug Discovery Center + Chemical Library	Drug discovery by identification and screening of drug molecules for various indications	Setting Up
AML Clinic	Clinic - Talem Medical	Medical Services	Commenced operations in June 2018

TALEM MEDICAL



Our Company has set up an outpatient clinic under the name of Talem Medical in Central, Hong Kong.

- Focus on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population.
- Clinic commenced operation in June 2018.

For illustrative purposes only. There is no guarantee that any project will have a specific outcome or will be completed.

IP AROUND LEAD PROGRAMS

PROJECT COMPANY / PROJECT NAME	LICENSOR(S)	LICENSEE	LICENSED / IP RIGHTS	PATENT EXPIRATION DATES
Acticule / ALS-1	Versitech Limited	Acticule Life Sciences Limited	Exclusive licensee: 1 U.S. patent (US9212177), 1 European Patent (EP2462138B1), 1 PRC patent (CN102596946B), 1 German patent (DE60 2010 019 171.0)	The licensed IP rights include granted patents in the U.S., Switzerland, Germany, Great Britain and PRC. The U.S. patent will expire in 2031; the European Patent in 2030; the PRC patent in 2030 and the German patent in 2030.
Acticule / ALS-4	Versitech Limited	Acticule Life Sciences Limited	Exclusive licensee: 1 pending U.S. application (16/041,836) and 1 pending PCT application (PCT/IB2018/055458), in which we intend to file national stage applications in PRC and before EPO prior to the 30-month entry deadline falling on January 2021.	The licensed IP rights include pending patent applications in the U.S. and under the PCT. Any patent based on the application, if granted, will have a 20-year patent term from 2018.
Nativus / NLS-1	1) PolyU Technology and Consultancy Company Limited 2) McGill University 3) Wayne State University 4) H. Lee Moffitt Cancer Center and Research Institute Inc. 5) The Chinese University of Hong Kong	Aptorum Therapeutics Limited	Exclusive licensee: 5 U.S. patents (US9713603, US7544816, US8193377, US8710248, US9169230), 1 European Patent (EP1778663), 1 PRC patent (CN101072764B), 1 Indian patent (IN263365) and 1 Japanese patent (JP5265915), as well as 1 pending U.S. application (US20170281591A1), 1 pending PRC application (CN104703596A), and 1 pending Hong Kong application (HK15111955.3)	The licensed IP rights include granted patents in the U.S., Switzerland, Germany, Great Britain, Ireland, Luxemburg, Monaco, PRC, India and Japan, as well as pending patent applications in the U.S., PRC and Hong Kong. The U.S., European and PRC patents covering the compound will expire in 2025; the indication U.S. patent will not expire until 2033.

FINANCIAL OVERVIEW

(US$) ROUNDED TO THE NEAREST THOUSAND		
Cash and restricted cash, and marketable securities	US$18,698,000 (as of 12/31/2017)	US$25,022,000 (as of 6/30/2018)
Intangible assets, net	US$1,473,000 (as of 12/31/2017)	US$1,452,000 (as of 6/30/2018)
Operating expenses	US$5,693,000 (ten months ended 12/31/2017)	US$4,901,000 (six months ended 6/30/2018)
Convertible debts	US$480,000 (as of 12/31/2017)	US$15,688,000 (as of 6/30/2018)

CAPITAL RAISED IN THE PAST 12 MONTHS

The above financials are extracted based on audited accounts for the ten months ended December 31, 2017 and unaudited accounts for the six months ended June 30, 2018. Past performance is not indicative of future results.

USE OF PROCEEDS

	USE OF NET PROCEEDS (Minimum offering amount of US$10) (in millions)	USE OF NET PROCEEDS (Maximum offering amount of US$30) (in millions)
Fund preclinical and clinical development:		
Development through Phase 1 of our Lead Projects[1]	approximately US$7.0	approximately US$18.0
Development of our non-therapeutics projects	approximately US$0.5	approximately US$3.0
Set up a self-owned laboratory in Fo Tan, Hong Kong	approximately US$1.0	approximately US$2.5
Fund other non-lead projects under development (other than non-therapeutic projects), general research and development activities, working capital and other general corporate activities	approximately US$0.5	approximately US$3.5

- [1]Estimated cost of US$5M - US$8M to develop one of our lead projects from current stage to completion of phase 1.
- Based on cash position as of June 30, 2018, estimated minimum unrestricted cash post IPO of approximately US$15.7m assuming minimum offering of US$10m is achieved.


APPENDIX

FINANCIAL OVERVIEW

SELECTED INCOME STATEMENT SUMMARY (US GAAP)

	Ten months ended December 31, 2017	Six months ended June 30, 2018
	US$	US$
Healthcare services income	-	26,662
Costs of healthcare services	-	22,749
Research and development expenses	2,560,323	1,342,179
General and administrative fees	1,480,093	2,238,025
Legal and professional fees	1,395,490	1,063,032
Other operating expenses	257,177	235,413
Total operating expense	5,693,083	4,901,398
Other income (loss)	3,131,576	-661,206
Net loss attributable to the Company's shareholders	-2,547,462	-5,488,372
Depreciation and amortisation	58,903	209,267

SELECTED BALANCE SHEET ITEMS (US GAAP)

	December 31, 2017	June 30, 2018
	US$	US$
Cash and restricted cash	16,725,807	22,927,198
Total current assets	20,283,399	26,371,722
Property, plant and equipment, net	346,587	4,211,321
Intangible assets, net	1,472,707	1,452,486
Total assets	31,559,982	41,465,225
Convertible debts	480,000	15,687,847
Total current liabilities	1,330,734	16,783,641
Total liabilities	1,330,734	16,949,778
Total shareholders' equity	30,229,248	24,515,447
Working capital*	18,952,665	9,588,081

* Total current assets less total current liabilities

The above financials are extracted based on audited accounts for the ten months ended December 31, 2017 and unaudited accounts for the six months ended June 30, 2018. Past performance is not indicative of future results.

APTORUM GROUP LIMITED
investor.relations@aptorumgroup.com
T +852 2117 6611
F +852 2850 7286

Boustead Securities
DANIEL McCLORY
Managing Director & Head of China and Equity Capital Markets
dan@boustead1828.com
+1 (949) 233-7869

China Renaissance
JOE LAI
Managing Director
Head of HK Healthcare IBD (HK)
joelai@chinarenaissance.com
+(852) 2287-1695

尚乘老虎 AMTD TIGER
MING LIN CHEUNG
Executive Director
minglin.cheung@amtdgroup.com
+(852) 9668-3557